Amesite’s NurseMagic™ Named Finalist for Nurse.org “Best of Nursing: AI Nursing Tool” Award
Rhea-AI Summary
Amesite (NASDAQ: AMST) said its AI healthcare platform NurseMagic™ was named a finalist in Nurse.org’s “Best of Nursing: AI Nursing Tool” award on March 4, 2026.
The company reported staged revenue acceleration: 2.4x QoQ after May 2025 launches, +82% and +69% in subsequent quarters, and 63% Enterprise growth; NurseMagic™ now scales to enterprise and launched an AI-native EMR in December 2025.
Positive
- 2.4x quarter-over-quarter revenue increase after May 2025 Teams+ and June 2025 upgrade
- Revenue rose 82% in the quarter after July 2025 Enterprise tier launch
- Follow-up quarter revenue growth of 69% quarter-over-quarter
- 63% revenue growth from NurseMagic Enterprise reported in September 2025
- Enterprise sales surpassed individual-user sales, signaling commercial scale
- Launched an AI-native NurseMagic EMR in December 2025
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Only one peer, CXAI, appears in momentum scans, moving up about 8.57%. No clear, broad sector move aligns with AMST’s modest 1.72% gain.
Previous AI Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 19 | EMR launch | Positive | +17.2% | Launched AI-native NurseMagic EMR targeting large post-acute market. |
| Sep 11 | Revenue growth update | Positive | +44.4% | Reported 63% NurseMagic Enterprise revenue growth and new AI form-fill tool. |
| Jun 25 | Product expansion | Positive | +0.0% | Expanded HIPAA-compliant NurseMagic to 16 languages with strong revenue growth. |
| Jan 30 | Marketing recognition | Positive | +8.5% | Nasdaq Times Square feature celebrating NurseMagic adoption in home health. |
| Dec 19 | Engagement surge | Positive | +3.0% | Reported sharp growth in social engagement and early enterprise contracts. |
AI-tagged NurseMagic news has generally seen positive price reactions, with one flat outcome despite upbeat fundamentals.
Over the past year, Amesite has repeatedly highlighted NurseMagic’s expansion, from rapid early adoption to enterprise and EMR rollouts. Prior AI-tagged releases showed strong revenue acceleration, including 2.4x quarterly growth, 63% revenue growth from Enterprise, and launch of the AI-native NurseMagic EMR targeting a post-acute market projected to exceed $850B. Those announcements often coincided with meaningful single-day stock gains, framing today’s award recognition as another step reinforcing the same growth narrative.
Historical Comparison
Prior AI-tagged NurseMagic releases averaged a 14.61% move. Today’s AI award news, with a 1.72% pre-event gain, sits below typical past AI reactions.
AI-tagged history shows NurseMagic progressing from initial launch and marketing traction, to multilingual expansion, then enterprise revenue scaling, and finally launch of an AI-native EMR for post-acute care.
Market Pulse Summary
This announcement highlights external validation for NurseMagic™, adding to a history of AI-focused launches, language expansion, and enterprise scaling. The article reiterates strong revenue growth metrics, while recent 10-Q filings show a net loss of $1.37 million over six months and going concern language alongside Nasdaq listing deficiencies. Investors may watch how award recognition translates into enterprise EMR adoption, revenue levels, cash trends, and progress toward meeting Nasdaq equity requirements.
Key Terms
post-acute care medical
emr medical
AI-generated analysis. Not financial advice.
AMST’s recognition from one of the largest online nursing communities follows step-change revenue growth as company targets a post-acute market expected to exceed
DETROIT, March 04, 2026 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST) today announced that its AI-powered healthcare platform, NurseMagic™, has been named a finalist in Nurse.org’s “Best of Nursing Awards” in the AI Nursing Tool category. The recognition from one of the largest online nursing communities comes less than two years after launch and as Amesite scales NurseMagic™ into the U.S. post-acute care market, which recent analyses estimate at roughly
Clinicians in post-acute care spend a significant share of their time on documentation and administrative tasks that are essential for reimbursement and compliance but reduce time available for direct care. NurseMagic™ addresses this problem with structured, AI-assisted documentation designed to help clinicians complete high-quality notes more efficiently while supporting organizational governance, defensibility, and scalability.
Amesite launched NurseMagic™ to individual nurses and caregivers first, rapidly scaling across all 50 states and multiple countries. This user-first strategy enabled the company to validate the product in daily clinical workflows before selling into enterprises, building a large, engaged community and generating the usage data required to harden the platform for post-acute operators.
Following the May 2025 launch of the NurseMagic™ Teams+ tier and a June 2025 product upgrade, the Company reported a 2.4x quarter-over-quarter increase in revenue. After the July 2025 launch of a census-based Enterprise tier, revenues increased
Today, less than 2 years since launch, NurseMagic™ supports post-acute providers seeking to reduce after-hours charting, improve documentation defensibility, and standardize workflows across home health, hospice, skilled nursing, and related settings. The platform’s architecture scales from individual clinicians to census-based enterprise deployments and an AI-native EMR, and is designed to reduce operational friction. The AI-native NurseMagic™ EMR, announced in December 2025, is designed to coexist with or replace legacy systems and to address a long-term care and post-acute software market that some forecasts expect to grow at double-digit annual rates through 2035.
“Serving nurses first is how we earned the right to serve post-acute,” said Madison Bush, Director of Corporate Operations at NurseMagic™. “We started by listening at scale to nurses, caregivers, and non-clinical staff using NurseMagic™ on real shifts. That community told us where AI was genuinely valuable, and their input shaped our workflows, governance, and pricing. We strongly believe that recognition by Nurse.org – less than 2 years after our beta launch – demonstrates value to both our customers and our shareholders.”
“As we’ve shared with investors, NurseMagic™’s revenue growth has come in clear stages, aligned with the rollout of progressively higher-value product tiers,” said Dr. Ann Marie Sastry, CEO of Amesite. “We went from assistant, to enterprise, to EMR based on what nurses and operators showed us they needed. Being named a finalist by Nurse.org is further external validation that the platform is solving real problems in a market measured in hundreds of billions of dollars. We believe that our AI-native EMR, built on this foundation, can capture meaningful share of the post-acute segment and continue to drive revenue growth.”
Voting for Nurse.org’s “Best of Nursing Awards” is currently open through the organization’s website. As a finalist for the “Best of Nursing: AI Nursing Tool” award, NurseMagic™ continues advancing its mission of giving nurses more time for patient care while helping healthcare organizations operate more efficiently, compliantly, and sustainably.
About Amesite Inc.
Amesite (NASDAQ: AMST) is an AI-driven software company focused on delivering technology platform solutions. Its flagship product, NurseMagic™, is designed to streamline clinical documentation, support point-of-care decision-making, and deliver actionable operational insight, and has expanded from an assistant for individual clinicians into an enterprise platform that includes an electronic medical record (EMR) offering. NurseMagic™ is used by used by over 100 professions across all 50 states and over 20 countries. Built on proprietary AI and designed to meet applicable regulatory and security requirements, the platform serves B2B and B2C users with capabilities that include workflow integration and multilingual support.
Forward-Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning the Company, the Company's planned online machine learning platform, the Company's business plans, any future commercialization of the Company's online learning solutions, potential customers, business objectives and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement. Risks facing the Company and its planned platform are set forth in the Company's filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations
ir@amesite.com
FAQ
What recognition did Amesite (AMST) receive for NurseMagic on March 4, 2026?
How did NurseMagic revenue change after the May–July 2025 product rollouts for AMST?
What market opportunity is Amesite targeting with NurseMagic (AMST)?
When did Amesite announce its AI-native NurseMagic EMR and what is its purpose?
Has NurseMagic shifted from individual users to enterprise sales for AMST?
How does NurseMagic aim to improve clinician workflows and documentation for AMST customers?
